Treatment

TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic breast cancer “TrasTUCAN Study”
This study is testing a new combination of medicines, Trastuzumab, Tucatinib, and Vinorelbine, for people with HER2-positive breast cancer that has spread or cannot be removed. Researchers want to see how well it shrinks cancer and if it's safe.
For: Non-resectable locally advanced or metastatic HER2-positive breast cancer
Spain